Search Articles — Sudonull

Search Results

In this project

Web Application Vulnerabilities: XSS SQLi enumeration

https://sudonull.com/web-application-vulnerabilities-xss-sqli-enumeration

Breakdown of top-3 vulnerabilities in web: user enumeration, XSS, SQL injections. Fix methods for developers: prepared statements, encoding. In-depth pentest guide.

Protection of agent applications OWASP Top 10

https://sudonull.com/protection-of-agent-applications-owasp-top-10

Analysis of OWASP Agentic Top 10 2026 and Lethal Trifecta for protecting AI agents. Countermeasures against goal hijack, RCE, memory poisoning. Practical roadmap for middle/senior dev.

Gamma Flip in Algorithmic Trading: Analysis and Application

https://sudonull.com/gamma-flip-in-algorithmic-trading-analysis-and-application

How Gamma Exposure Determines Market Regimes and Volatility. Calculation of Net GEX, Interpretation of Gamma Flip, Practical Recommendations for Traders.

C4 model for IT infrastructure: practical application

https://sudonull.com/c4-model-for-it-infrastructure-practical-application

How to adapt the C4 model for designing fault-tolerant clusters. Critical errors at the HLD stage and methods to prevent them. Guide for engineers.

From other projects

Pediatric Dovato: EMA Approves Application for HIV Therapy

https://ymaho.com/pediatric-dovato-ema-approves-application-for-hiv-therapy

EMA validated the application for pediatric Dovato (dolutegravir/lamivudine) for children from 2 years old. Learn how two-drug therapy is changing HIV treatment standards.

EMA accepted the application for Dovato for children with HIV

https://ymaho.com/ema-accepted-the-application-for-dovato-for-children-with-hiv

EMA validated the application for the use of Dovato in children from 3 months with HIV. Learn how this will change pediatric therapy and strengthen ViiV's position. Read the detailed analysis.

Study of the Ottava robot: FORTE results and FDA application

https://ymaho.com/study-of-the-ottava-robot-forte-results-and-fda-application

Scientists have completed the pivotal study of the Ottava robot (FORTE) and are preparing an FDA application. Learn about clinical data, zero conversions, and market prospects for robotic surgery.

Gene therapy for deafness otarmeni EMA: accelerated review 2026

https://ymaho.com/gene-therapy-for-deafness-otarmeni-ema-accelerated-review-2026

EMA accepted the application for gene therapy otarmeni for the treatment of hereditary deafness OTOF. Market analysis, forecasts, price and implications for the industry. Read.

SpaceX IPO: filing for $75 billion and valuation of $1.75 trillion

https://ymaho.com/spacex-ipo-filing-for-75-billion-and-valuation-of-1-75-trillion

SpaceX filed an application for the largest IPO in history on Nasdaq up to $75 billion. Valuation $1.75 trillion, listing in June 2026. Analysis of the record, consequences and hidden details. Read more.

Intellia CRISPR therapy: FDA filing for lonvo-z for HAE

https://ymaho.com/intellia-crispr-therapy-fda-filing-for-lonvo-z-for-hae

Intellia has filed the world's first application for an in vivo CRISPR therapy, lonvo-z, for hereditary angioedema (HAE). 87% reduction in attacks, 62% attack-free. Risk, market, and forecast analysis. Read.

Revision of MiCA: why ART stablecoins did not take off

https://ymaho.com/revision-of-mica-why-art-stablecoins-did-not-take-off

The European Commission has started a revision of MiCA due to zero applications for ARTs. Reasons for failure and forecasts for stablecoins. Find out what will change by 2027.

From the web

Microsoft Community

https://answers.microsoft.com/en-us/windows/forum/all/windows-only-has-2-restore-points-despite-lots-of/9902e91e-0dfb-4805-9c73-21d8ed7cb059

Microsoft Community

https://www.answers.microsoft.com/en-us/windowslive/forum/all/unable-to-receive-verification-email/17348df3-1ff9-4f1f-a6e2-5d695671e05c

Microsoft Community

https://www.answers.microsoft.com/ja-jp/windows/forum/all/フォトギャ/b45f8dde-aa4a-4598-ab6e-21a67f8b6ec2

Trending Now